Newsletter
Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

JAMA Editor’s Summary

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the issue.
December 21, 2021
ADVERTISEMENT
Support your Favorite Podcasts Leave a Review

Newer →

Minimally Invasive Surfactant Therapy for Preterm Infants, First Attempt Intubation in Critically Ill Patients, Prevalence and Treatment of Diabetes in China, and more

← Older

Intravenous or Intraosseous Calcium for Out-of-Hospital Cardiac Arrest, Closure of Patent Foramen Ovale After Stroke, Clinical Outcomes in Preserved Ratio Impaired Spirometry, and more
Buffer LinkedIn WhatsApp

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 21, 2021 issue.

ADVERTISEMENT
ADVERTISEMENT

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Silver Sponsors

Bronze Sponsors

Event and Media Partners

Buffer LinkedIn WhatsApp
00:00
00:00